Skip to main content
. 2013 Sep 9;8(9):e73672. doi: 10.1371/journal.pone.0073672

Figure 1. BSO potentiates HCH induced cytotoxicity in leukemic cells.

Figure 1

(A) K562 cells were incubated with varying concentrations of HCH (left panel) and BSO (right panel) for 48 h and viability was determined by (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Structures of HCH and BSO are shown within the respective graphs. * p<0.05 compared to treatment with vehicle control; ** p<0.01 compared to vehicle control. (B) K562 cells were simultaneously treated with varying concentration of BSO and HCH for 48 h. * p<0.05 compared to HCH treatment alone; ** p<0.01 compared to treatment with HCH alone; *** p<0.001 compared to HCH treatment alone; # p<0.01 compared to treatment with vehicle control or BSO. (C) Leukemic cell lines were incubated with BSO and HCH either alone or in combination for 48 h. *** p<0.001 compared to treatment with vehicle control or either of the compounds alone. (D) Same as (C) except that non-leukemic cancer cell lines were used instead of leukemic cell lines. (E) Normal cell lines or normal human peripheral blood mononuclear cells (hPBMC) were incubated with BSO and HCH either alone or in combination for 48 h. (F) PBMC from one normal donor and 3 CML patients were incubated with BSO and HCH either alone or in combination for indicated time periods and viability was determined by trypan blue dye exclusion assay. ** p<0.01 and *** p<0.001 compared to treatment with vehicle control or either of the compounds alone respectively. (A)-(F) Data represent mean ± SD of quadruplicate wells. (G) Isobologram analysis for the determination of synergy using Calcusyn software.